Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516879 · ClinicalTrials.gov registry record · Phase 3
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 905
- Enrollment target
NCT01516879 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 905 participants.
The verdict
NCT01516879, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 905 participants
- Enrollment target
Study Summary
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
Interventions
- BIOLOGICAL Placebo
- DRUG Ezetimibe
- DRUG Atorvastatin
- OTHER Diet Only
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2012-01-05 |
| Est. Completion | 2013-10-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01516879
The ClinicalTrials.gov registry entry for NCT01516879 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 905 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01516879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01516879 about?
NCT01516879 is a clinical study titled "Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study". To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
What is the current status of trial NCT01516879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2012-01-05. Estimated completion is 2013-10-14.
What interventions are being tested in trial NCT01516879?
The interventions under investigation include: Placebo (BIOLOGICAL), Ezetimibe (DRUG), Atorvastatin (DRUG), Diet Only (OTHER), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01516879?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.